nct_id,nlm_download_date_description,study_first_submitted_date,results_first_submitted_date,disposition_first_submitted_date,last_update_submitted_date,study_first_submitted_qc_date,study_first_posted_date,study_first_posted_date_type,results_first_submitted_qc_date,results_first_posted_date,results_first_posted_date_type,disposition_first_submitted_qc_date,disposition_first_posted_date,disposition_first_posted_date_type,last_update_submitted_qc_date,last_update_posted_date,last_update_posted_date_type,start_month_year,start_date_type,start_date,verification_month_year,verification_date,completion_month_year,completion_date_type,completion_date,primary_completion_month_year,primary_completion_date_type,primary_completion_date,target_duration,study_type,acronym,baseline_population,brief_title,official_title,overall_status,last_known_status,phase,enrollment,enrollment_type,source,limitations_and_caveats,number_of_arms,number_of_groups,why_stopped,has_expanded_access,expanded_access_type_individual,expanded_access_type_intermediate,expanded_access_type_treatment,has_dmc,is_fda_regulated_drug,is_fda_regulated_device,is_unapproved_device,is_ppsd,is_us_export,biospec_retention,biospec_description,ipd_time_frame,ipd_access_criteria,ipd_url,plan_to_share_ipd,plan_to_share_ipd_description,created_at,updated_at
NCT04045808,"ClinicalTrials.gov processed this data on November 29, 2019",2019-08-02,,,2019-08-02,2019-08-02,2019-08-06,Actual,,,,,,,2019-08-02,2019-08-06,Actual,"April 12, 2009",Actual,2009-04-12,August 2019,2019-08-31,"February 2, 2011",Actual,2011-02-02,"January 1, 2011",Actual,2011-01-01,,Observational,,,Relationship of Oral Status to Coronary Artery Disease,Associate Professor,Completed,,,309.0,Actual,Baskent University,,,2.0,,f,,,,,f,f,,,,,,,,,,,2019-11-30 20:36:04.245223,2019-11-30 20:36:04.245223
NCT04040660,"ClinicalTrials.gov processed this data on November 29, 2019",2019-07-26,,,2019-07-31,2019-07-31,2019-08-01,Actual,,,,,,,2019-07-31,2019-08-01,Actual,,,,July 2019,2019-07-31,,,,,,,,Expanded Access,NEXT,,Use of NexoBrid for Treatment of Acute Deep Partial and Full Thickness Burn Injuries,Use of NexoBrid for Treatment of Acute Deep Partial and Full Thickness Burn Injuries,Available,,,,,MediWound Ltd,,,,,,,,t,,,,,,,,,,,,,,2019-11-30 20:36:38.905407,2019-11-30 20:36:38.905407
NCT04035161,"ClinicalTrials.gov processed this data on November 29, 2019",2019-07-10,,,2019-08-27,2019-07-26,2019-07-29,Actual,,,,,,,2019-08-27,2019-08-29,Actual,,,,,,,,,,,,,,,,[Trial of device that is not approved or cleared by the U.S. FDA],[Trial of device that is not approved or cleared by the U.S. FDA],Withheld,,,,,[Redacted],,,,,,,,,,,,,,,,,,,,,,2019-11-30 20:37:16.337747,2019-11-30 20:37:16.337747
NCT03914872,"ClinicalTrials.gov processed this data on November 29, 2019",2019-04-08,,,2019-04-12,2019-04-12,2019-04-15,Estimate,,,,,,,2019-04-12,2019-04-15,Estimate,,,,April 2019,2019-04-30,,,,,,,,Expanded Access,,,Expanded Access Neoantigen Vaccine in Solid Tumors,Expanded Access Neoantigen Vaccine in Solid Tumors,Temporarily not available,,,,,Washington University School of Medicine,,,,,f,,,t,,,,,,,,,,,,,,2019-11-30 20:52:24.512451,2019-11-30 20:52:24.512451
NCT04179097,"ClinicalTrials.gov processed this data on November 29, 2019",2019-09-30,,,2019-11-25,2019-11-25,2019-11-26,Actual,,,,,,,2019-11-25,2019-11-26,Actual,"November 5, 2019",Actual,2019-11-05,September 2019,2019-09-30,"June 1, 2020",Anticipated,2020-06-01,"December 1, 2019",Anticipated,2019-12-01,1 Day,Observational [Patient Registry],,,Photoplethysmographic Dichrotic Notch Reflexes Systemic Hemodynamics,Dichrotic Notch Positioning in Finger Photoplethysmography Waveform Reflex Systemic Vascular Resistance,Recruiting,,,15.0,Anticipated,Hospital Privado de Comunidad de Mar del Plata,,,,,f,,,,t,f,f,,,,,,,,,No,,2019-11-30 20:20:48.591068,2019-11-30 20:20:48.591068
NCT04179084,"ClinicalTrials.gov processed this data on November 29, 2019",2019-11-07,,,2019-11-25,2019-11-25,2019-11-26,Actual,,,,,,,2019-11-25,2019-11-26,Actual,"August 28, 2019",Actual,2019-08-28,November 2019,2019-11-30,"May 1, 2020",Anticipated,2020-05-01,"March 1, 2020",Anticipated,2020-03-01,,Interventional,,,Phase II Study to Evaluate the Efficacy and Safety of Fruquintinib Plus Sintilimab as Third-line Therapy for Colorectal Cancer,Phase II Study to Evaluate the Efficacy and Safety of Fruquintinib Plus Sintilimab as Third-line Therapy for Colorectal Cancer,Recruiting,,Phase 2,30.0,Anticipated,Chinese PLA General Hospital,,1.0,,,f,,,,,f,f,,,,,,,,,No,,2019-11-30 20:20:49.7302,2019-11-30 20:20:49.7302
NCT04179071,"ClinicalTrials.gov processed this data on November 29, 2019",2019-11-25,,,2019-11-25,2019-11-25,2019-11-26,Actual,,,,,,,2019-11-25,2019-11-26,Actual,"December 12, 2019",Anticipated,2019-12-12,November 2019,2019-11-30,"March 19, 2020",Anticipated,2020-03-19,"March 19, 2020",Anticipated,2020-03-19,,Interventional,,,A Study in Healthy Male Subjects to Understand How Savolitinib Behaves Inside the Body (Pharmacokinetics) When Administered Alone and in Combination With Famotidine,"An Open-Label, Randomised, Two Part, Two Treatment Crossover Study in Healthy Subjects to Assess the Pharmacokinetics of Savolitinib When Administered Alone and in Combination With Famotidine",Not yet recruiting,,Phase 1,32.0,Anticipated,AstraZeneca,,2.0,,,,,,,f,t,f,,,,,,,,,,,2019-11-30 20:20:49.784263,2019-11-30 20:20:49.784263
NCT03613363,"ClinicalTrials.gov processed this data on November 29, 2019",2018-07-09,,,2019-11-13,2018-07-27,2018-08-03,Actual,,,,,,,2019-11-13,2019-11-15,Actual,,,,,,,,,,,,,,,,[Trial of device that is not approved or cleared by the U.S. FDA],[Trial of device that is not approved or cleared by the U.S. FDA],Withheld,,,,,[Redacted],,,,,,,,,,,,,,,,,,,,,,2019-11-30 21:32:14.823014,2019-11-30 21:32:14.823014
NCT04179058,"ClinicalTrials.gov processed this data on November 29, 2019",2019-11-18,,,2019-11-25,2019-11-25,2019-11-26,Actual,,,,,,,2019-11-25,2019-11-26,Actual,March 2020,Anticipated,2020-03-31,November 2019,2019-11-30,September 2020,Anticipated,2020-09-30,September 2020,Anticipated,2020-09-30,,Observational,EVOLIPAF,,Interstitial Pneumonia With Autoimmune Features: Evaluation of Connective Tissue Disease Incidence During Follow-up,Interstitial Pneumonia With Autoimmune Features: Evaluation of Connective Tissue Disease Incidence During Follow-up,Not yet recruiting,,,300.0,Anticipated,"Central Hospital, Nancy, France",,,2.0,,f,,,,f,f,f,,,,,,,,,No,,2019-11-30 20:20:49.85274,2019-11-30 20:20:49.85274
